RSS-Feed abonnieren
DOI: 10.1055/s-0034-1396312
Vorhofflimmern nach Herzoperation: Wie und wie lange behandeln?
Atrial Fibrillation after Cardiac Surgery – How to Treat and How Long?Publikationsverlauf
Publikationsdatum:
14. April 2015 (online)
Zusammenfassung
Vorhofflimmern ist eine der häufigsten Komplikationen nach herzchirurgischen Eingriffen. Als Risikofaktoren gelten die gleichen, die auch sonst zu Vorhofflimmern prädisponieren, vor allem höheres Lebensalter, bekanntes Vorhofflimmern und eine arterielle Hypertonie. Daneben steigt mit der Komplexität des Eingriffs auch das postoperative Vorhofflimmerrisiko. Neben dem unabhängig von der Operation vorhandenen Substrat werden Sympathikusaktivierung, Entzündungsreaktionen und oxidativer Stress als Trigger diskutiert. Hier setzen auch die prophylaktischen Maßnahmen an, insbesondere die Fortsetzung oder präoperative Initiierung einer Betablockertherapie. Tritt Vorhofflimmern auf, stehen die Embolieprophylaxe mit Heparin oder nicht Vitamin-K-abhängigen Antikoagulanzien (NOAC) bzw. Phenprocoumon in Abwägung des Blutungsrisikos und Medikamente zur Frequenzkontrolle im Vordergrund, hier v. a. Betablocker. Da bei vielen Patienten mit postoperativem Vorhofflimmern kein Rezidiv zu erwarten ist, sollte die Indikation zur Fortführung der eingeleiteten Therapie einschließlich der Antikoagulation 6–12 Wochen nach Operation auf ihre weitere Notwendigkeit überprüft werden. Da Vorhofflimmerrezidive oftmals asymptomatisch sind, sollte andererseits das Beenden einer dauerhaften Antikoagulation besonders kritisch hinterfragt werden. Zumindest mehrere Langzeit-EKG-Kontrollen erscheinen vor Absetzen einer Antikoagulation sinnvoll.
Abstract
Atrial fibrillation (AF) after cardiac surgery is a common complication. Risk factors equal those predisposing to AF, namely advanced age, history of AF and hypertension. Risk for postoperative AF also increases with the type of cardiac surgery. In addition to a pre-existing substrate, increased sympathetic tone, inflammation and oxidative stress have been identified as triggers for postoperative AF. Prophylactic measures aim at attenuating these triggers and include continuation or initiation of preoperative beta-blocker therapy. If AF occurs, initiation of anticoagulation after assessment of the individual stroke and bleeding risk and medication for heart rate control – based on symptoms and left ventricular function – are the main therapeutic goals. As postoperative AF is self-limiting in most patients, they often do not require long-term treatment. That is why therapy prescribed for these purposes should be re-evaluated 6 to 12 weeks after surgery. Because AF is often asymptomatic, discontinuation of oral anticoagulation in particular requires careful evaluation. Serial Holter-ECG to detect AF appear reasonable prior to discontinuation.
-
Literatur
- 1 Maesen B, Nijs J, Maessen J et al. Postoperative atrial fibrillation: a maze of mechanisms. Europace 2012; 14: 159-174
- 2 Kanji S, Williamson DR, Yaghchi BM et al. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care 2012; 27: 326.e1-326.e8
- 3 Mitchell LB. CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fribrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011; 27: 91-97
- 4 Aranki SF, Shaw DP, Adams DH et al. Predictors of atrial fibrillation after coronary artery surgery: Current trends and impact of hospital resources. Circulation 1996; 94: 390-397
- 5 Danelich IM, Lose JM, Wright SS et al. Practical management of postoperative atrial fibrillation after noncardiac surgery. J Am Coll Cardiol Surg 2014; 219: 831-841
- 6 Connolly SJ, Cybulsky I, Lamy A et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. Am Heart J 2003; 145: 226-232
- 7 Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27: 2846
- 8 Windecker S, Kolh P, Alfonso F et al. Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619
- 9 Bagshaw SM, Galbraith PD, Mitchell LB et al. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 2006; 82: 1927-1937
- 10 Buckley MS, Nolan PE, Slack MK et al. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007; 27: 360-368
- 11 Imazio M, Brucato A, Ferrazzi P et al. COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA 2014; 312: 1016-1023
- 12 Liakopoulos OJ, Choi YH, Kuhn EW et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678-686
- 13 Camm AJ, Kirchhof P, Lip GY et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420
- 14 Costanzo S, di Niro V, Di Castelnuovo A et al. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: an updated meta-analysis. J Thorac Cardiovasc Surg 2013; 146: 906-911
- 15 El-Chami MF, Kilgo P, Thourani V et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 2010; 55: 1370-1376
- 16 Healey JS, Brambatti M. Periprocedural management of oral anticoagulation in patients with atrial fibrillation: approach in the era of new oral anticoagulants. Can J Cardiol 2013; 29 (Suppl. 07) S54-S59